Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-NYM215 in NENs
Sponsor: Peking Union Medical College Hospital
Summary
This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms. An head-to-head comparison with 68Ga-DOTATATE PET/CT will assess the diagnostic performance of 68Ga-NYM215 PET/CT at both the patient and lesion levels.
Official title: Safety, Biodistribution, Dosimetry of 68Ga-NYM215 PET/CT and Head-to-head Comparison With 68Ga-DOTATATE PET/CT in Patients With Neuroendocrine Neoplasms: A Prospective Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-09-10
Completion Date
2027-10-20
Last Updated
2026-09-23
Healthy Volunteers
No
Conditions
Interventions
68Ga-NYM215 PET/CT
40 patients will be enrolled in this arm. Each patients will be injected with approximately 3mCi 68Ga-NYM215. The first 8 participants will undergo serial 68Ga-NYM215 PET imaging at 5, 15, 30, 45, 60, and 120 minutes after 68Ga-NYM215 administration. Subsequent participants will undergo whole-body 68Ga-NYM215 PET/CT at 40 to 60 minutes after administration.
68Ga-DOTATATE PET/CT
Each patients will be injected with approximately 3mCi 68Ga-DOTATATE. All participants will undergo whole-body 68Ga-DOTATATE PET/CT at 40 to 60 minutes after radiotracer administration. The two PET/CT examinations will be performed within 1 week, with an interval of at least 24 hours to minimize potential cross-interference.
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China